abbmira therapeutics AG

Abbmira Therapeutics AG is a Basel-based biotechnology company founded in 2024 that focuses on developing first-in-class small-molecule immunomodulators. The company's technology is designed to fine-tune the native immune system by reprogramming tumor-associated macrophages (TAMs) from an immune-suppressive, pro-tumor state to an anti-tumor state. Its lead candidate, Compound42, utilizes a novel mechanism to reshape the tumor microenvironment, aiming to overcome the limitations of existing cancer therapies that often fail due to drug resistance and immune evasion. By targeting specific immune pathways, the company seeks to deliver durable anticancer responses across various oncology and chronic disease indications.

The development of these therapeutics addresses significant unmet medical needs in cancer treatment, where tumors frequently exploit native immune cells to shield themselves from attack. Abbmira’s approach is supported by preclinical proof-of-concept studies showing the inhibition of cancer growth in mouse models. The company is currently engaged in optimizing its therapeutic approach and advancing its molecules toward clinical development. As an active member of the Swiss biotech ecosystem, Abbmira is working to translate its research into clinical applications while actively seeking collaborations with investors and scientific partners to support its R&D initiatives.